Compare GLP-1 Weight Loss Medications
Side-by-side facts to discuss with your provider
Semaglutide vs Tirzepatide
Two GLP-1 class medications used for weight management
Medication Comparison
| Feature | Semaglutide | Tirzepatide |
|---|---|---|
| Active Ingredient | Semaglutide | Tirzepatide |
| Mechanism | GLP-1 receptor agonist | Dual GIP/GLP-1 receptor agonist |
| FDA-approved branded version exists | ||
| Compounded version FDA-approved | ||
| Weight Loss (branded product clinical trials) | ~15% | ~20% |
| Dosing Frequency | Once weekly | Once weekly |
| Time to Max Dose | 16-20 weeks | 20-24 weeks |
| Lito program price (published, same at every dose) | $99/month | $134/month |
Weight loss figures come from clinical trials of the FDA-approved branded products (STEP and SURMOUNT). Compounded semaglutide and tirzepatide are not FDA-approved, do not undergo FDA review for safety, effectiveness, or manufacturing quality, and are not substitutes for the branded drugs. Individual results vary.
About Semaglutide
- GLP-1 receptor agonist with a longer track record
- Gradual titration schedule
- ~15% average weight loss in branded-product trials
- Often where providers start first-time GLP-1 patients
About Tirzepatide
- Dual GIP/GLP-1 receptor agonist
- ~20% average weight loss in branded-product trials
- Longer titration to maximum dose
- Sometimes considered after a plateau on semaglutide, at a provider's discretion